Search Results - "Fratte, S."

Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR) by Basile, D., Broudin, C., Emile, J.F., Falcoz, A., Pagès, F., Mineur, L., Bennouna, J., Louvet, C., Artru, P., Fratte, S., Ghiringhelli, F., André, T., Derangère, V., Vernerey, D., Taieb, J., Svrcek, M.

“…Histological characteristics at the invasive front may reflect tumor aggressiveness; specifically, tumor budding (Bd) is an emerging prognostic biomarker in…”
Get full text

2345 Neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (dcf) compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma by Kim, S, Paget-Bailly, S, Fiteni, F, Messager, M, Nguyen, T, Mathieu, P, Lamfichekh, N, Fein, F, Fratte, S, Cleau, D, Calcagno, F, Lakkis, Z, Jary, M, Sakek, N, Jacquin, M, Foubert, A, Bonnetain, F, Mariette, C, Borg, C

Get full text

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients by Taieb, J, Balogoun, R, Le Malicot, K, Tabernero, J, Mini, E, Folprecht, G, Van Laethem, J-L, Emile, J-F, Mulot, C, Fratté, S, Levaché, C-B, Saban-Roche, L, Thaler, J, Petersen, L N, Bridgewater, J, Perkins, G, Lepage, C, Van Cutsem, E, Zaanan, A, Laurent-Puig, P

“…RAS mutations have been shown to confer resistance to anti- epidermal growth factor receptor (EGFR) treatment. We analysed the results of the PETACC8 trial…”
Get full text

Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402) by Doffoël, M, Bonnetain, F, Bouché, O, Vetter, D, Abergel, A, Fratté, S, Grangé, J.D, Stremsdoerfer, N, Blanchi, A, Bronowicki, J.P, Caroli-Bosc, F.X, Causse, X, Masskouri, F, Rougier, P, Bedenne, L

“…Abstract The FFCD 9402 multicentre phase III trial was designed to compare the effects of the combination of Transarterial Lipiodol Chemoembolisation (TACE)…”
Get full text

Perioperative Docetaxel, Cisplatin, and 5-Fluorouracil Compared to Standard Chemotherapy for Resectable Gastroesophageal Adenocarcinoma by Kim, Stefano, Paget-Bailly, Sophie, Messager, Mathieu, Nguyen, Thierry, Mathieu, Pierre, Lamfichekh, Najib, Fein, Francine, Fratté, Serge, Cléau, Denis, Lakkis, Zaher, Jary, Marine, Sakek, Nacera, Jacquin, Marion, Foubert, Audrey, Bonnetain, Franck, Mariette, Christophe, Fiteni, Frederic, Borg, Christophe

“…Abstract Background Even though the perioperative chemotherapy improves the overall survival (OS) compared to surgery alone in patients with a resectable…”
Get full text

P-281 Safety analysis and preliminary clinical results of REPROGRAM-01 phase II study evaluating regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer by Borg, C., Klajer, E., El Kaddissi, A., Ghiringhelli, F., Kim, S., Vernerey, D., Henriques, J., Nguyen, T., Meurisse, A., Fratte, S., Fein, F., Spehner, L., Rebucci-Peixoto, M., Vienot, A.

Get full text

388MO Tumor budding, an important prognostic factor in stage III colon cancer patients treated with oxaliplatin-based chemotherapy by Basile, D., Broudin, C., Emile, J-F., Falcoz, A., Toullec, C., Bennouna, J., Louvet, C., Desrame, J., Fratte, S., André, T., Taieb, J., Svrcek, M.

Get full text

509TiP REPROGRAM-01, a phase II study of regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer by Klajer, E., Jary, M., Borg, C., Kim, S., Vernerey, D., Henriques, J., N'Guyen, T., Nasri, M., Almotlak, H., Babre, J., Meurisse, A., Fratte, S., Fein, F., Calcagno, F., Chanut, L., Spehner, L., Rebucci-Peixoto, M., Vienot, A.

Get full text

Function of the active-site lysine in Escherichia coli serine hydroxymethyltransferase by SCHIRCH, D, DELL FRATTE, S, IURESCIA, S, ANGELACCIO, S, CONTESTABILE, R, BOSSA, F, SCHIRCH, V

“…Serine hydroxymethyltransferase has a conserved lysine residue (Lys-229) that forms the internal aldimine with pyridoxal 5'-phosphate. In other pyridoxal…”
Get full text

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials by Barbier, Emilie, François, Eric, Michel, Pierre, Rougier, Philippe, Seitz, Jean-François, Aouakli, A., Bedjaoui, A., Botton, A., Cadier-Lagnes, A., Hollebecque, A., Lemaire, A., Marre, A., Villing, A.L., Denis, B., Becht, C., Bineau, C., Borel, C., Buffet, C., Cornila, C., Couffon, C., Locher, C., Rebischung, C., Sarda, C., Auby, D., Baudet-Klepping, D., Besson, D., Cleau, D., Festin, D., Genet, D., Peré-Vergé, D., Pillon, D., Smith, D., Dorval Danquechin, E., Maillard, E., Mitry, E., Suc, E., Zrihen, E., Pariente, E.A., Dewaele, F., Di Fiore, F., Husseini, F., Kikolski, F., Petit-Laurent, F., Zerouala-Boussaha, F., Caroli-Bosc, F.X., Boilleau-Jolimoy, G., Medinger, G., Graber, I., Charneau, J., Cretin, J., Deguiral, J., Lacourt, J., Meunier, J., Vincent, J., Volet, J., Barbare, J.C., Paitel, J.F., Raoul, J.L., Gornet, J.M., Aucouturier, J.P., Barbieux, J.P., Plachot, J.P., Ramain, J.P., Spano, J.P., Bouhier-Leporrier, K., Cany, L., Rob, L., Baconnier, M., Benchalal, M., Combe, M., Duluc, M., Giovannini, M., Mabro, M., Ramdani, M., Tissot, M., Clavero-Fabri, M.C., Gouttebel, M.C., Kaminsky, M.C., Stremsdoerfer, N., Burtin, P., Cassan, P., Claudé, P., Couzigou, P., Geoffroy, P., Godeau, P., Hammel, P., Novello, P., Prost, P., Ruszniewski, P., Texereau, P., Coriat, R., Nasca, S., Fratte, S.P., Mansourbakht, T., Walter, T., Derias, V., Jestin Le Tallec, V., Sebbagh, V., Adhoute, X., Becouarn, Y.

“…Previous studies showed that high and low body mass index (BMI) was associated with worse prognosis in early-stage colorectal cancer (CRC), and low BMI was…”
Get full text

Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results by Taieb, J., Bonnetain, F., Mineur, L., Bennouna, J., Desrame, J., Faroux, R., Fratte, S., Dauba, J., Vernerey, D., Louvet, C., Lepere, C., Dupuis, O., Becouarn, Y., Mabro, M., Egreteau, J., Bouche, O., Deplanque, G., Ychou, M., de Gramont, A., André, T.

Get full text

The structure of serine hydroxymethyltransferase as modeled by homology and validated by site‐directed mutagenesis by Pascarella, Stefano, Angelaccio, Sebastiana, Contestabile, Roberto, Fratte, Sonia Delle, Salvo, Martino Di, Bossa, Francesco

“…We describe a model for the three‐dimensional structure of E. coli serine hydroxymethyltransferase based on its sequence homology with other PLP enzymes of…”
Get full text

Comparative ultrastructural study of rat livers preserved in Euro-Collins or University of Wisconsin solution by Fratté, S, Gendrault, J L, Steffan, A M, Kirn, A

“…University of Wisconsin solution greatly lengthens the time liver storage is possible compared with all previous solutions used. To test whether this…”
Get more information

Bifractionated CPT-11 with LV5FU2 Infusion (FOLFIRI-3) In Combination with Bevacizumab Followed by a Capecitabine and Bevacizumab Maintenance Therapy: A Phase II Study in First-Line Metastatic Colorectal Cancers by Kim, C.H.S., Curti, E., Nguyen, T., Maurina, T., Lakkis, Z., Heyd, B., Dobi, E., Fratte, S., Winkfield, B., Borg, C.

Get full text

600P - Bifractionated CPT-11 with LV5FU2 Infusion (FOLFIRI-3) In Combination with Bevacizumab Followed by a Capecitabine and Bevacizumab Maintenance Therapy: A Phase II Study in First-Line Metastatic Colorectal Cancers by Kim, C.H.S., Curti, E., Nguyen, T., Maurina, T., Lakkis, Z., Heyd, B., Dobi, E., Fratte, S., Winkfield, B., Borg, C.

“…Bevacizumab (Bev) with FOLFIRI or FOLFOX regimen is a standard of care in first-line metastatic colorectal cancers (mCRC). As second-line regimen after FOLFOX,…”
Get full text

Prognostic Value of Angiopoietin-2 for Overall Survival in Patients with Metastatic Colorectal Carcinoma Treated By Chemotherapy and Bevacizumab by Jary, M., Vernerey, D., Dobi, E., Monnien, F., Godet, Y., Kim, S., Bouché, O., Fratte, S., Ghiringhelli, F., Goncalvez, A., Lecomte, T., Leger, J., Queiroz, L., Adotevi, O., Bonnetain, F., Borg, C.

Get full text

211PPROGNOSTIC VALUE OF ANGIOPOIETIN-2 FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA TREATED BY CHEMOTHERAPY AND BEVACIZUMAB by Jary, M., Vernerey, D., Dobi, E., Monnien, F., Godet, Y., Kim, S., Bouché, O., Fratte, S., Ghiringhelli, F., Goncalvez, A., Lecomte, T., Leger, J., Queiroz, L., Adotevi, O., Bonnetain, F., Borg, C.

“…Abstract Aim: Angiogenesis is implicated in carcinogenesis and tumor progression. Angiopoietin-2 (Ang-2) is a protein involved in the regulation of vascular…”
Get full text

Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy by Fiteni, Frédéric, Jary, Marine, Monnien, Franck, Nguyen, Thierry, Beohou, Eric, Demarchi, Martin, Dobi, Erion, Fein, Francine, Cleau, Denis, Fratté, Serge, Nerich, Virginie, Bonnetain, Franck, Pivot, Xavier, Borg, Christophe, Kim, Stefano

“…Gemcitabine/Cisplatin (Gem/CDDP) combination has demonstrated a clear survival advantage over gemcitabine alone and has become a new standard in advanced…”
Get full text

Purification and properties of serine hydroxymethyltransferase from Sulfolobus solfataricus by Delle Fratte, S, White, R H, Maras, B, Bossa, F, Schirch, V

“…Article Usage Stats Services JB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Serine hydroxymethyltransferase: role of the active site lysine in the mechanism of the enzyme by Schirch, D, Delle Fratte, S, Iurescia, S, Angelaccio, S, Contestabile, R, Bossa, F, Schirch, V

Get more information